Compare CSIQ & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSIQ | ETON |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.4M | 689.8M |
| IPO Year | 2006 | 2018 |
| Metric | CSIQ | ETON |
|---|---|---|
| Price | $16.49 | $28.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | $17.36 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 2.4M | 314.4K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | $23.61 | $40.90 |
| Revenue Next Year | $13.90 | $47.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $8.84 | $13.09 |
| 52 Week High | $34.59 | $27.29 |
| Indicator | CSIQ | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 69.27 |
| Support Level | $15.93 | $16.79 |
| Resistance Level | $17.07 | N/A |
| Average True Range (ATR) | 1.14 | 1.28 |
| MACD | 0.49 | -0.05 |
| Stochastic Oscillator | 93.72 | 84.79 |
Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.